{{Rsnum
|rsid=477692
|Gene=MGMT
|Chromosome=10
|position=131426022
|Orientation=minus
|GMAF=0.4509
|Gene_s=MGMT
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 31.0 | 49.6 | 19.5
| HCB | 19.0 | 43.1 | 38.0
| JPT | 18.6 | 56.6 | 24.8
| YRI | 53.7 | 38.8 | 7.5
| ASW | 41.1 | 44.6 | 14.3
| CHB | 19.0 | 43.1 | 38.0
| CHD | 17.4 | 39.4 | 43.1
| GIH | 13.9 | 52.5 | 33.7
| LWK | 37.3 | 50.9 | 11.8
| MEX | 40.4 | 42.1 | 17.5
| MKK | 37.2 | 47.4 | 15.4
| TSI | 24.5 | 52.0 | 23.5
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23047291
  |Trait=Response to temozolomide
  |Title=A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
  |RiskAllele=
  |Pval=1E-8
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}